TEL AVIV, Israel
April 3, 2013
Bioassociate has released valuation coverage on RedHill Biopharma, Ltd. (NASDAQ: RDHL) (TASE:RDHL.TA). The Report contains a detailed discussion of RedHill's business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks. The valuation Report is available at:
, Bioassociate's CEO:
"RedHill is developing late clinical-stage, improved and patented formulations of e
xisting drugs. RedHill's most advanced clinical program, RHB-103 - a fast dissolving thin film formulation of rizatriptan for the treatment of migraine, submitted for FDA review by the end of Q1 2013. RedHill's Pipeline is diverse and features six late stage clinical programs that address multi-billion dollar markets. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with successful track record at big and small pharmaceutical companies. RedHill recently completed registration of its ADRs on the Nasdaq Global Market.
We see great potential in RedHill's business platform and clinical development programs. We anticipate deal making activities in the near future with RedHill's advanced clinical programs. For these reasons we, at Bioassociate, reached to a target price of
per share, which reflects an upside of 38% over the current share price."
Bioassociate is an independent investment research firm specialized in the life-science sector. Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage. Bioassociate structures its teams with multidisciplinary members to conduct specific assignments. The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.
The research report described in this press release is not constructed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer would be illegal. Bioassociate is not soliciting any action based upon this material. It does not take into account the particular investment objectives, financial situation, risk profile or other needs of individual investors. Before acting on any advice or recommendation in this material, an investor should consider whether it is suitable for his/her particular circumstances and, if necessary, seek professional advice. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such. Opinions expressed are Bioassociate's current opinions as of the date appearing on this material only; such opinions are subject to change without notice. RedHilll is a client of Bioassociate and is paying Bioassociate a cash fee for Bioassociate's services, which include the preparation of equity research and valuation reports. The research report is based on public information and on information provided by RedHill, which according to RedHill is available publicly.